PRACTICAL EVALUATION OF THE EFFICACY AND NEEDS OF COVID-19 VACCINES
DOI:
https://doi.org/10.11603/2411-1597.2022.1.12864Abstract
The article represents the information on modern vaccines against COVID-19, laboratory control of the formation of post-infectious and post-vaccine immunity, based on the analysis of different literary references. A lot of statements of the manufacturers on the efficiency level of vaccines, expressed as a percentage, are now available. Those data are most likely about the level of formation of protective immunity to SARS-CoV-2 after vaccination in a certain proportion of individuals who received the particular type of vaccine, and they vary widely from 50 to 95 %. In order to objectify this assessment, it is suggested to focus on the blood level of anticoagulant IgG, expressed in «Binding antibody units» per unit volume – BAU/ml. At «average» and «above average» levels of anticoagulant IgG (more than 200 BAU/ml) vaccination can and should be delayed. The vaccination of individuals with «low» levels of anti-IgG (up to 50 BAU/ml) is in paramount concern.
References
WHO. Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process. – 20 January 2021. – https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_20Jan2021_v2.pdf
WHO. Draft landscape and tracker of COVID-19 candidate vaccines. – 9 April 2021. – https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vacciness
Супотницкий М. В. Неугодная иммунология / М. В. Супотницкий // Актуальная инфектология. – 2016. – № 2 (11). – С. 73–97.
Anti-Spike protein assays to determine post-vaccination antibody levels: a head-to-head comparison of five quantitative assays / T. Perkmann, N. Perkmann-Nagele, T. Koller [et al.]. – https://doi.org/10.1101/2021.03.05. 21252977
WHO International Standard. First WHO International Standard for anti-SARS-CoV-2 immunoglobulin (human) NIBSC code: 20/136. Instructions for use (Version 2.0, Dated 17/12/2020). – https://www.nibsc.org/documents/ifu/20-136.pdf
WHO Reference Panel. First WHO International Reference Panel for anti-SARS-CoV-2 immunoglubulin. NIBSC code: 20/268. Instructions for use (Version 3.0, Dated 17/12/2020). – https://www.nibsc.org/documents/ifu/20-268.pdf
Особливості гуморальної імунної відповіді при коронавірусній хворобі (COVID-19) / О. М. Зінчук, А. В. Петрух, Н. І. Гринчишин, К. К. Шваєвська // Актуальная инфектология. – 2021. – Т. 9, № 1. – С. 33–36.
Recommendations for the preparation, characterization and establishment of international and other biological reference standards (revised 2004). Annex 2. In: WHO Expert Committee on Biological Standardization: fifty-fifth report. WHO Technical Report Series 932. – 2004: Geneva, Switzerland. P. 73–131. – https://www.who.int/bloodproducts/catalogue/en/
Харченко Е. П. Коронавирус SARS-CoV-2: особенности структурных белков, контагиозность и возможные иммунные коллизии / Е. П. Харченко // Эпидемиология и вакцинопрофилактика. – 2020. – Т. 19 (2). – С. 13–30.
Creech C. B. SARS-CoV-2 Vaccines / C. B. Creech, Sh. C. Walker, R. J. Samuels // JAMA. – 2021. – Vol. 325 (13). – P. 1318–1320. – doi:10.1001/jama.2021.3199
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Nursing
This work is licensed under a Creative Commons Attribution 4.0 International License.
